Bortezomib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bortezomib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
1162
Registered trials
1226
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Bortezomib can convert its Small molecule drug profile and Proteasome biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bortezomib (query alias: bortezomib) |
|---|---|
| Modality / target | Small molecule drug; Proteasome; Proteasome inhibitors |
| Highest global status | Approved |
| Originator | Millennium Pharmaceuticals, Inc. |
| Active developers | Celgene Corp., Accord Healthcare SL, Janssen-Cilag Pty Ltd. |
The MCP disease footprint includes Immunoglobulin Light-Chain Amyloidosis, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07635511 | Phase 3 | Not yet recruiting | 42 | The response rate for anti-HLA antibody clearance |
| NCT07652905 | Phase 2 | Not yet recruiting | 24 | Minimal residual disease (MRD) negative rate |
| NCT07675174 | Phase 1/2 | Not yet recruiting | 72 | Phase I |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Adjunctive and post-transplant doxycycline in systemic light-chain (AL) amyloidosis.
Not Applicable; n=906; evaluation: Negative. Reported fields: all-cause mortality(10-year): RR = 0.67(95.0% CI, 0.42 - 1.07); all-cause mortality(10-year): RR = 0.67(95.0% CI, 0.42 - 1.07); all-cause mortality(10-year): RR = 0.67(95.0% CI, 0.42 - 1.07)
LEN-EOS study: Lenalidomide-associated eosinophilia as a marker of response to induction therapy in multiple myeloma.
Not Applicable; n=127; evaluation: Positive. Reported fields: CR = 27.1 % ; CR = 50.0 %
Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.
Phase 1/2; n=47; evaluation: Positive. Reported fields: DLT = DLT (all grade 4 neutropenia) was noted in 3 pts, 2 at DL 1 & 1 at DL -1
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bortezomib addresses Immunoglobulin Light-Chain Amyloidosis, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-09-05 | Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration | Approved | Financial terms not disclosed |
| 2021-12-17 | Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories | Approved | US$75.0M upfront; US$202.5M milestones; US$277.5M stated total |
| 2008-04-11 | Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion | Approved | US$8,800.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Solvent-free, ready-to-use formulation of bortezomib”. The milestone feed surfaced a patent-application signal described as “Stable liquid bortezomib formulations”. The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with proteasome inhibitors”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
